Efficacy and safety of an NRTI-sparing dual regimen of raltegravir and ritonavir-boosted protease inhibitor in a triple antiretroviral class-experienced population

HIV Clin Trials. 2009 Sep-Oct;10(5):337-40. doi: 10.1310/hct1005-337.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Cohort Studies
  • Drug Therapy, Combination
  • Female
  • HIV / drug effects
  • HIV Infections / drug therapy*
  • HIV Protease Inhibitors / adverse effects*
  • Humans
  • Male
  • Middle Aged
  • Pyrrolidinones / adverse effects*
  • Raltegravir Potassium
  • Ritonavir / adverse effects*
  • Treatment Outcome

Substances

  • HIV Protease Inhibitors
  • Pyrrolidinones
  • Raltegravir Potassium
  • Ritonavir